Agendia to Use Rosetta Resolver for Biomarker Discovery, Sees Promise in Downstream Utility | GenomeWeb

Rosetta Biosoftware has dipped a toe in the microarray-based diagnostics market in an agreement with Agendia that it announced last week.

Agendia, based in Amsterdam, is the developer of MammaPrint, a gene expression-profiling service that assesses the risk of breast cancer recurrence. Initially, Agendia plans to use Rosetta Resolver in its R&D pipeline to discover new gene expression signatures for future diagnostics, but the diagnostics company is hoping to eventually move the software downstream into clinical use.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.